Galecto forms R&D Committee, boosts non-executive Chair option grant to 36,000 shares

Damora Therapeutics, Inc.

R&D Committee established; members receive $7,500/yr retainer, Chair gets additional $7,500/yr.
Non-Executive Chair annual option grant increased from 18,000 to 36,000 shares; other directors remain at 18,000.
Initial equity award of 18,000 options vests over 36 months; annual award vests over 12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.